WuXi AppTec (2359) released its third quarter 2025 results. According to the announcement, revenue for the first three quarters of 2025 reached approximately RMB 32.86 billion, representing an 18.6% increase compared with the same period last year. Net profit attributable to the owners of the Company for the first three quarters of 2025 rose to about RMB 12.08 billion, up 84.8% year-over-year. In the third quarter alone, revenue stood at around RMB 12.06 billion, a 15.3% increase year-over-year, while net profit attributable to the owners of the Company was approximately RMB 3.51 billion, up 53.3% from the prior year.

During the first three quarters, continuing operations contributed strongly to overall performance, growing 22.5% year-over-year to RMB 32.45 billion. WuXi Chemistry reported revenue of roughly RMB 25.98 billion, a 29.3% increase, driven by expansions in small-molecule projects and TIDES-related capabilities. WuXi Testing recorded revenue of about RMB 4.17 billion, while WuXi Biology saw revenue of approximately RMB 1.95 billion.

By the end of September 2025, backlog for continuing operations stood at around RMB 59.88 billion, a 41.2% increase year-over-year. The Company attributed the rise in net profit to factors including enhanced capacity efficiency in late-stage clinical and commercial projects, as well as partial disposal of equity interests in an associate. The Company also noted it anticipates double-digit growth for continuing operations revenue through the remainder of the year, raising its full-year total revenue target range to RMB 43.5–44.0 billion.